Reccurent/Metastatic Solid Tumor Disease
Conditions
Keywords
Metastatic/Reccurent, Solid Tumor, Refractory, Molecular profile, Targeted treatment
Brief summary
SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer. From a tumor biopsy, a molecular profile of the disease is established (mutations, amplifications, hormone receptor status). If a molecular abnormality is identified for which an approved targeted agent is available, patients are randomized randomized between two arms: * Targeted therapy based on the molecular profile * Conventional therapy based on investigator's choice. A cross-over is proposed at disease progression.
Interventions
DRUGTargeted therapy based on molecular profiling : Imatinib
PROCEDURETumor biopsy
DRUGStandard Chemotherapy
DRUGTargeted therapy based on molecular profiling : Everolimus
DRUGTargeted therapy based on molecular profiling : Vemurafenib
DRUGTargeted therapy based on molecular profiling : Sorafenib
DRUGTargeted therapy based on molecular profiling : Erlotinib
DRUGTargeted therapy based on molecular profiling : Lapatinib + Trastuzumab
DRUGTargeted therapy based on molecular profiling : Dasatinib
DRUGTargeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)
DRUGTargeted therapy based on molecular profiling : Abiraterone
Sponsors
Institut Curie
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient with recurrent/metastatic solid tumor who failed or are not candidate for treatments usually proposed in first intentions and for whom a prospective clinical trial has been indicated in a tumor board 2. ECOG performance status of 0 or 1 3. Biopsiable disease (tumor biopsy mandatory for tumor profiling). The biopsy can be performed when patients are being treated with standard therapy for their recurrent/metastatic cancer if it is not planned to treat them with molecularly targeted agents in the future. 4. Measurable disease 5. Adequate renal function defined by a serum creatinine \<1.5xUNL (upper normal limit) 6. Adequate liver function test defined by SGOT & SGPT \<3xUNL (5xUNL in case of liver metastases), and bilirubin level \<1.5xUNL 7. Adequate bone marrow function defined by platelets \>100,000/mm3, hemoglobin \>10 g/dL, and neutrophils \>1,000/mm3 8. Patients must be affiliated to the French Social Security System 9. Signed informed consent 10. For female of child-bearing potential: a negative pregnancy test \<72 hours before starting study treatment is required. If sexually active, female of childbearing potential must use highly effective methods of contraception for the study duration and for 3 months following the last treatment 11. For male of reproductive potential: any sexually active male patient must use a condom while on study treatment and for 3 months following the last treatment 12. Agreement to send the CD-ROMs of imaging for central review
Exclusion criteria
1. Patients who have only bone and/or brain metastases 2. Patients whose brain metastases have not been controlled for \>3 months 3. Patient participating in another clinical trial with an experimental drug 4. Patients who are candidate to receive a molecularly targeted agent that is approved for their disease 5. Anticoagulation with anti-vitamin K (Low Molecular Weight Heparin \[LMWH\] is allowed) 6. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, including uncontrolled diabetes, cardiac disease, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infection within one year, chronic liver or renal disease, active gastrointestinal tract ulceration, severely impaired lung function 7. Pregnant and/or breastfeeding women 8. Individually deprived of liberty or placed under the authority of a tutor 9. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 10. Known HIV, HBV, or HCV infection Eligibility criteria for the randomized part : 1. Identification of tumor molecular abnormalities for which the Therapeutic Decision Committee (TDC) recommends a molecularly targeted therapy available in the context of the trial (even if the molecular profile is incomplete) 2. Therapy recommended by the TDC is not approved for the patient's disease 3. ECOG performance status of 0 or 1 4. Adequate renal function defined by a serum creatinine \<1.5xUNL 5. Adequate liver function tests defined by SGOT & SGPT \<3xUNL (5xUNL in case of liver metastases), and bilirubin level \<1.5xUNL 6. Adequate bone marrow function defined by platelets \>100,000/mm3, hemoglobin \>8 g/dL, and neutrophils \>1,000/mm3 7. Albumin, LDH and number of metastatic sites have been documented (in order to determine the RMH prognostic score) 8. LVEF \>50% 9. QTc \<480 ms on ECG
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy. | — | Tumor evaluation according to RECIST 1.1 criteria (every 2 months) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | — | — |
| Treatments side effects assessement according to the NCI CTCAE v4.03 scale. | — | — |
| Treatment effect variations as defined by tumor growth according to the altered signaling pathway | — | Evaluation of tumor growth before and during the study (according to RECIST 1.1) |
| Overall response rate (ORR) | — | Tumor evaluation according to RECIST 1.1 criteria (every 2 months) |
| Evaluation of the ability of ctDNA to early predict treament efficacy | — | Comparing treatment efficacy to ctDNA level (before and during treatment course) |
| Evaluation of the medico-economic impact of the experimental strategy | — | — |
| Technical feasability of the SHIVA trial: number of screened patient compared to number of patients elligible to randomization. | — | Number of screened patients. Number of patient with a molecular full profil in the timeframe (4 weeks between tumor biopsy and SHIVA's committees decision). Number of randomized patient. |
| Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy after cross-over. | — | Tumor evaluation according to RECIST 1.1 criteria (every 2 months) |
Countries
France
Outcome results
None listed